Investment Strategy - Beijing Chunlizhengda Medical Instruments Co., Ltd. reported significant investments in structured deposit products, with a total investment amount of RMB 67,000,000 across various banks[2]. - The company has maintained a focus on utilizing idle fundraising for investment in structured deposits, enhancing liquidity management[3]. - The company continues to explore further investment opportunities in structured financial products to optimize asset allocation[4]. - The structured deposits are part of the company's broader financial strategy to ensure capital preservation and yield enhancement[4]. - The investment in structured deposit products is aimed at effectively utilizing temporarily idle funds raised from the public offering of A-shares, enhancing the overall capital return of the group[5]. Financial Performance - The annualized return for the structured deposits from Beijing Bank ranged from 1.35% to 1.6%, with actual returns reported at 3.2% for some products[2][3]. - The actual returns from structured deposits were reported as RMB 126.25 million, RMB 236.71 million, and RMB 196.03 million, reflecting positive investment outcomes[2][3]. - The company recorded investment income from structured deposit products of approximately RMB 6,748,000 and fair value changes of structured deposit products amounting to approximately RMB 9,491,000 as of December 31, 2022[5]. - As of December 31, 2022, the balance of structured deposit products was RMB 765,000,000, with a fair value of approximately RMB 767,728,000, accounting for about 23% of the company's total assets[5]. Cash Management - The company fully redeemed all structured deposits by the end of the reporting period, indicating effective cash management strategies[2][3]. - The company's core objectives include ensuring capital security and maintaining liquidity[5]. Banking Relationships - The company has established relationships with reputable banks, ensuring reliable investment channels for its financial products[4]. Monitoring and Future Objectives - The financial performance and investment strategies will be closely monitored to align with future growth objectives[4]. - The supplementary information provided does not affect other data disclosed in the 2022 annual report[5].
春立医疗(01858) - 2023 - 年度业绩